Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Acetylcysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.62 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 5/20 | 0.43 |
| ▸ | NOS1 | P29475 | 4/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcysteine SCHEMBL893717 | 1.00 | BLM (0.62) | BLMKDM4EMAPTTHRBALOX15 | |
| Acetylcysteine SCHEMBL663169 | 1.00 | BLM (0.62) | BLMKDM4EMAPTTHRBALOX15 | |
| Acetylcysteine SCHEMBL27772811 | 0.95 | KDM4E (0.64) | BLMKDM4EMAPTTHRBALOX15 | |
| Lysine SCHEMBL18006519 | 0.89 | GSR (0.65) | BLMKDM4EMAPTTHRBALOX15 | |
| Lysine SCHEMBL18006518 | 0.89 | GSR (0.65) | BLMKDM4EMAPTTHRBALOX15 | |
| Acetylcysteine SCHEMBL9016357 | 0.84 | ALOX15 (0.70) | BLMKDM4EMAPTTHRBALOX15 | |
| Acetylcysteine SCHEMBL28342967 | 0.84 | ALOX15 (0.70) | BLMKDM4EMAPTTHRBALOX15 | |
| Acetylglutamic Acid SCHEMBL11756644 | 0.84 | FOLH1 (0.64) | GSRSIRT6SIRT1FOLH1CYP1A2 | |
| SCHEMBL21828643 | 0.83 | GSR (0.55) | BLMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL14957758 | 0.83 | GSR (0.55) | BLMKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | WUHAN VAST CONDUCT SCIENCE FOUNDATION CO., LTD. (CN) | 2026-05-26 | — | — | US | claimed |
| US-12533378-B2 | Treatment of adverse effects caused by atypical antipsychotics | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-01-27 | — | — | US | claimed |
| US-12410477-B2 | Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders | NATIONAL JEWISH HEALTH (US) | 2025-09-09 | — | — | US | claimed |
| US-20250249036-A1 | Composition and Method for treatment of diabetes | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECH CO LTD (CN) | 2025-08-07 | — | — | US | claimed |
| US-12310985-B2 | Composition and method for treatment of diabetes | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECHNOLOGY (CN) | 2025-05-27 | — | — | US | claimed |
| US-20250009856-A1 | METHODS FOR TREATING RESPIRATORY DISEASES | MUCPharm Pty Ltd (AU) | 2025-01-09 | — | — | US | claimed |
| US-20240423948-A1 | 5-HYDROXYMETHYLFURFURAL FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | D-CAP LLC (US) | 2024-12-26 | — | — | US | claimed |
| EP-4135721-B1 | TREATMENT OF ADVERSE EFFECTS CAUSED BY ATYPICAL ANTIPSYCHOTICS | SHENZHEN PROFOUND VIEW PHARMACEUTICAL TECH CO LTD (CN) | 2024-11-20 | — | — | EP | claimed |
| US-20240337645-A1 | METHODS OF TREATING COMPROMISED LUNG FUNCTION AND ASSESSING CLINICAL IMPROVEMENT | THE TRUSTEES OF INDIANA UNIVERSITY | 2024-10-10 | — | — | US | claimed |
| WO-2024199144-A1 | NOVEL REAGENT FOR MITIGATING LNP TOXICITY | SHANGHAI MOYIN THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | WO | claimed |
| US-7090870-B1 | Dry power inhaler excipient, process for its preparation and pharmaceutical compositions containing it | VANDERBIST FRANCIS | 2006-08-15 | — | — | US | claimed |
| EP-1658063-A1 | ADVANTAGEOUS COMBINATIONS FOR INHALATION OF NACYSTELYN AND BRONCHODILATORS | Galephar M/F (BE) | 2006-05-24 | — | — | EP | claimed |
| EP-1603615-A1 | IMPROVED DRY POWDER INHALER SYSTEM | Galephar M/F (BE) | 2005-12-14 | — | — | EP | claimed |
| US-20050154060-A1 | Anti-inflamatory inhalation pharmaceutical composition | GALEPHAR PHARMACEUTICAL RESEARCH, INC. (US) | 2005-07-14 | — | — | US | claimed |
| WO-2005013963-A1 | ADVANTAGEOUS COMBINATIONS FOR INHALATION OF NACYSTELYN AND BRONCHODILATORS | GALEPHAR M/F (BE) | 2005-02-17 | — | — | WO | claimed |
| WO-2004082750-A1 | IMPROVED DRY POWDER INHALER SYSTEM | GALEPHAR M/F (BE) | 2004-09-30 | — | — | WO | claimed |
| EP-0964675-B1 | DRY POWDER INHALER EXCIPIENT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | PHARLYSE SA (LU) | 2003-09-03 | — | — | EP | claimed |
| EP-0964675-A1 | DRY POWDER INHALER EXCIPIENT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | "PHARLYSE", Société Anonyme (LU) | 1999-12-22 | — | — | EP | claimed |
| WO-1998050015-A1 | DRY POWDER INHALER EXCIPIENT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | PHARLYSE, SOCIETE ANONYME (LU) | 1998-11-12 | — | — | WO | claimed |
| EP-0876814-A1 | Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it | "PHARLYSE", Société Anonyme (LU) | 1998-11-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533378-B2 | Treatment of adverse effects caused by atypical antipsychotics | FABP7, FABP4, LIPC | PTGS2 4612/4885PTGS1 4509/4885BLM 4834/4885 |
| US-12636312-B2 | Gold clusters (AuCs), composition and method for treatment of liver cirrhosis | FABP1, ALB, CSTB | PTGS2 1807/4885PTGS1 2062/4885BLM 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.